Home
About
Conversations
Live Coverage
Campaigns
< Go Back
Topic: clinical study
November 16, 2016
Bayer Announces Phase III Study to Evaluate New Pediatric Formulation of Nifurtimox for Potential Treatment of Chagas Disease
Tags:
Bayer
,
Chagas
,
clinical study
,
nifurtimox
Got something to add?
Submit Now
Sign up
for the Daily Delivery
MENU
Home
About
Conversations
Live Coverage
Campaigns
FHI 360
Tweet
Tweet
Tweet
Tweet
Tweet
Tweet